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Background: Various injectable bulking agents have been used for the treatment of faecal incontinence
(FI). However, encouraging early results are not maintained over time. This study aimed to assess short-
and medium-term results of a new bulking agent for the treatment of FI.
Methods: The Gatekeeper
TM
prosthesis comprises a thin solid polyacrylonitrile cylinder that becomes
thicker, shorter and softer within 24 h after implantation.Fourteen patients with FI underwent treatment
with Gatekeeper
TM under local anaesthesia. Four prostheses were implanted in the intersphincteric space
in each patient, under endoanal ultrasound guidance. Number of episodes of major FI, Cleveland Clinic
FI score (CCFIS), Vaizey score, anorectal manometry, endoanal ultrasonography (EUS), health status
and quality of life (Short Form 36 and Faecal Incontinence Quality of Life questionnaires) were assessed
before and after treatment.
Results: Mean(s.d.) follow-up was 33·5(12·4) months. There were no complications. There was a
signiﬁcant decrease in major FI episodes from 7·1(7·4) per week at baseline to 1·4(4·0), 1·0(3·2) and
0·4(0·6) per week respectively at 1-month, 3-month and last follow-up (P = 0·002). CCFIS improved
signiﬁcantly from 12·7(3·3) to 4·1(3·0), 3·9(2·6) and 5·1(3·0) respectively (P < 0·001), and Vaizey score
from 15·4(3·3) to 7·1(3·9), 4·7(3·0) and 6·9(5·0) respectively (P = 0·010). Soiling and ability to postpone
defaecation improved signiﬁcantly, and patients reported signiﬁcant improvement in health status and
quality of life. At follow-up, manometric parameters had not changed and EUS did not demonstrate any
prosthesis dislocation.
Conclusion: The Gatekeeper
TM anal implant seemed safe, reliable and effective. Initial clinical
improvement was maintained over time, and follow-up data were encouraging.
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Introduction
Faecal incontinence (FI) is a common problem that can
present with a wide variety of symptoms ranging from
involuntary but recognized passage of gas, liquid or solid
stool to unrecognized anal leakage of mucus, ﬂuid or
stool. Depending on the degree of symptoms, FI can be
a highly distressing and socially incapacitating problem.
The wide variety of aetiologies and difﬁculty in accurately
deﬁning the cause of the problem make treatment difﬁcult.
Appropriate treatment relies on accurate diagnosis and
careful patient selection. Various injectable anal bulking
agents have been used to treat FI1–7, but procedures
have not been standardized, and the most effective site
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of placement as well as the amount of agent to be delivered
has yet to be established. Moreover, depending on the
material used, dislocation, migration and absorption can
occur. Owing to signiﬁcant differences between bulking
agents and clinical conditions in which they are used,
results are controversial and difﬁcult to interpret. It seems
that early positive results of anal bulking agents are often
not conﬁrmed in the long term.
This aim of this study was assess the short- and medium-
term results of a new bulking agent used for the treatment
of FI.
Methods
This study, carried out at the Department of Surgical
Sciences, Catholic University, Rome, was approved by the
institutional ethics committee.
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Anal bulking agent
Gatekeeper
TM
prostheses(originallyfromMedtronic,Min-
neapolis, Minnesota, USA; now from THD, Correg-
gio, Italy) were used as anal bulking agent. These are
thin solid cylinders (length 21 mm, diameter 1·2 mm) of
HYEXPAN
TM
(polyacrylonitrile), a hydrophilic material
that,within24 hofimplantationincontactwithhumantis-
sue,changesshapeandvolume,becomingthicker(diameter
7 mm), shorter (length 17 mm) and of softer consistency
(Fig. 1). Their ﬁnal shape yields a 720 per cent volume
increase compared with the volume inserted. The material
is identiﬁable on palpation and ultrasonography.
Selection criteria and preoperative data collection
Patients with at least a 6-month history of episodes
of FI (soiling or incontinence to liquid and/or solid
stools) occurring at least once a week that had failed
to improve with conservative measures were invited to
participate. Patients with isolated incontinence to gas,
risk of signiﬁcant postoperative complications, including
uncontrolled diabetes, anal sepsis, inﬂammatory bowel
diseases with anorectal involvement or any colorec-
tal cancer undergoing active treatment, were excluded.
Patients with an isolated external anal sphincter (EAS)
defect demonstrated on endoanal ultrasonography (EUS)
were also excluded. Patient selection was based on data
collected from the history, physical examination, conti-
nence diary recorded for 14 days (assessing incontinence
episodes to gas, liquid and solid stool; postevacuation
soiling episodes; and inability to postpone defaecation),
Cleveland Clinic FI score (CCFIS)8 and Vaizey score9.
Further information on health status and quality of life
was obtained from questionnaires: Short Form 36 health
survey (SF-36; QualityMetric, Lincoln, Rhode Island,
USA)10 and Faecal Incontinence Quality of Life (FIQL)11.
All patients were assessed with anorectal manometry and
EUS.
Implantation technique
The procedure was performed as a day case, under
local anaesthesia using a posterior perineal block with
the patient placed in the lithotomy position. Four 2-
mm skin incisions were made at 3, 6, 9 and 12 o’clock
positions in the perianal area 2 cm from the anal verge.
With an Eisenhammer retractor inserted in the anal
canal, a dedicated introducer formed by an introducer
guide and an external sheath (Fig. 2) was tunnelled from
the skin incision to the intersphincteric margin, and
advanced into the intersphincteric space until the tip
of the introducer reached the level of the puborectalis
muscle. The introducer guide was removed, leaving the
sheath in the intersphincteric space. The prosthesis was
inserted into the lumen of the introducer sheath and
advanced. When the prosthesis reached the middle–upper
anal canal the introducer sheath was removed, leaving the
prosthesis in place. The same procedure was repeated
for all four positions. All prosthesis placement steps
were carried out under direct vision and under EUS
guidance (Model 1850 equipped with a system for
a  Before implantation b  24 h after implantation
Fig. 1 Gatekeeper
TM
prosthesis a before implantation and b 24 h after implantation
 2011 British Journal of Surgery Society Ltd www.bjs.co.uk British Journal of Surgery 2011; 98: 1644–1652
Published by John Wiley & Sons Ltd1646 C. Ratto, A. Parello, L. Donisi, F. Litta, V. De Simone, L. Spazzafumo and P. Giordano
a  Guide–sheath assembly
b  Prosthesis in sheath
c  Prosthesis released from sheath
d  EUS check for position of prostheses
Fig. 2 Implantation of Gatekeeper
TM
prosthesis: a metal guide and external sheath assembled together; b following removal of the metal
guide, the prosthesis is introduced through the sheath; c the prosthesis is released from the sheath; d the position of the prosthesis is
checked by endoanal ultrasonography (EUS) at the end of the procedure
three-dimensional reconstruction; B-K Medical, Herlev,
Copenhagen, Denmark). At the end of procedure, the
correct positioning of the prostheses was conﬁrmed by
EUS (Fig. 2). After the procedure patients were discharged
home, with advice to avoid heavy physical activity for at
least 48 h. All patients received oral antibiotic prophylaxis
for 3 days.
Follow-up
Patients were reviewed in outpatients at 7, 30 and 90 days,
and 6 months thereafter. All patients were recalled for
further evaluation at the time of study closure. Anorectal
manometry was performed at 30 and 90 days, and at
ﬁnal follow-up. Each patient kept a continence diary
for 14 days before the follow-up appointments 30 and
90 days after operation and the last follow-up. Data
obtained from the continence diary were used to calculate
the CCFIS and Vaizey score. At the last follow-up
appointment patients were also asked to complete the
SF-36 and FIQL questionnaires. All adverse events
occurring during the ﬁrst 3 months after the procedure
were recorded.
Study endpoints
The primary endpoint was safety of the surgical
technique assessed as intraoperative and postoperative
complications, prosthesis displacement and any other
morbidity. Secondary endpoints were therapeutic efﬁcacy
of Gatekeeper
TM
injection in terms of improvement in
FI symptoms, changes in manometric parameters, and
changes in health status and quality of life.
Statistical analysis
Continuous data were presented as mean(s.d.), and
compared using the Wilcoxon test. Fisher’s exact test
was used for analysis of categorical data. P < 0·050 was
considered statistically signiﬁcant. Analyses were carried
out with SPSS version 12.0 software for Windows
(SPSS, Chicago, Illinois, USA).
Results
Fourteen consecutive patients (6 men, 8 women) with a
mean age of 63·5(17·0) (range 28–83) years were enrolled
from May 2005 to January 2008. Table 1 shows the history,
and baseline clinical and quality-of-life data. All eight
women enrolled in the study had given birth, two by
caesarean and six by vaginal delivery; four of the vaginal
deliveries included an episiotomy.
Postevacuation soiling was reported to occur always in
nine patients, sometimes in two, rarely in two and never
in one patient. The mean number of major incontinence
episodes was 7·1(7·4) per week overall, 6·2(6·0) per week
to liquids and 0·9(1·4) per week to solids. The mean
CCFIS was 12·7(3·3) (range 7–18); only three patients had
a CCFIS below 10. The mean Vaizey score was 15·4(3·3)
(range 11–21). Patients could postpone defaecation for a
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Table 1 Baseline clinical features
No. of patients*
History
Anal surgery‡ 5
Anal trauma 2
Abdominal surgery 3
Diabetes 3
Pelvic radiotherapy 1
Faecal incontinence
Age at onset (years)† 53·9(18·6)
Duration (months)† 11·6(8·6)
Ability to defer defaecation (min)† 6·1(4·9)
<50
5–10 2
11–20 4
>20 8
Postdefaecation soiling
Often/always 9
Sometimes 2
Never/rarely 3
Incontinence to gas (episodes/week)† 21·2(15·1)
Incontinence to liquid (episodes/week)† 6·2(6·0)
Incontinence to solids (episodes/week)† 0·9(1·4)
Need to wear pad
Always/often 6
Sometimes 0
Rarely/never 8
Lifestyle alteration
Always/often 12
Sometimes 1
Rarely/never 1
CCFIS† 12·7(3·3)
Vaizey score† 15·4(3·3)
Quality of life†
SF-36
Physical function 62·8(22·3)
Role physical 25·0(41·6)
Bodily pain 84·3(24·9)
General health 32·0(24·4)
Vitality 50·7(22·9)
Social function 29·5(23·3)
Role emotional 19·0(36·3)
Mental health 44·0(26·5)
FIQL score
Lifestyle 1·76(0·47)
Coping and behaviour 1·37(0·38)
Depression and self-perception 2·07(0·57)
Embarrassment 1·53(0·64)
*Unless indicated otherwise; †values are mean(s.d.). ‡Lateral internal
sphincterotomy in three patients, haemorrhoidectomy in three,
ﬁstulotomy in two. CCFIS, Cleveland Clinic faecal incontinence score;
FIQL, Faecal Incontinence Quality of Life.
mean of 6·1(4·9) min. EUS demonstrated no sphincter
injury in eight patients, an isolated internal anal sphincter
(IAS) defect in four, and a combined IAS and EAS defect in
two patients (the latter patients both had an episiotomy
during childbirth). Baseline anal manometric data are
reported in Table 2.
All procedures were carried out successfully as a day
case. Mean duration of operation was 35(7) min, including
local anaesthesia, surgical procedure and control EUS. In
all patients, the procedure proved to be easy and safe, and
EUSconﬁrmedaccurateprosthesisplacement.Therewere
no intraoperative complications.
Postoperative features
There was no postoperative morbidity. None of the
patients experienced any degree of local or systemic
sepsis, fever or pain. There was no evidence of any
acute or chronic inﬂammatory response around the
implanted prostheses. Neither prosthesis dislodgement
nor mucosal/skin alteration (ﬁstula, ulceration) was noted.
Patients experienced no anal discomfort either at rest or
during defaecation.
Follow-up
Overall median follow-up was 33·5(12·4) (range 5–48)
months. One week after Gatekeeper
TM
implantation,
clinicalassessment bydigitalexaminationandEUSshowed
the absence of acute inﬂammation at the prosthesis sites.
All but one patient reported a signiﬁcant improvement and
regarded the treatment as successful. In one patient with
an IAS defect secondary to lateral internal sphincterotomy
the number of episodes of FI remained relevant (28 per
week at baseline, 14 per week at 1 month and 12 per week
at 3 months); 5 months after Gatekeeper
TM
implantation
this patient underwent successful sacral nerve stimulation
and was excluded from further analysis.
The mean total number of episodes of major FI
decreased signiﬁcantly immediately after surgery and
the improvement was maintained over time, with a
change from 7·1(7·4) per week before operation to
1·4(4·0), 1·0(3·2) and 0·4(0·6) per week at 1-month,
3-month and last follow-up respectively (P = 0·002).
Findings were similar when episodes of incontinence
to liquids or solids were analysed separately (Fig. 3).
Postevacuation soiling and ability to postpone defaecation
also improved signiﬁcantly: before treatment three of
14 patients never or rarely experienced postevacuation
soiling, whereas nine of 13 patients reported absence of
postevacuation soiling at the last follow-up (P = 0·028)
(Fig. 4). Defaecation could be delayed for a signiﬁcantly
longer period following treatment, from a baseline of
6·1(4·9) min to 21·9(13·8 )m i na tl a s tf o l l o w - u p( P <
0·031).
Mean CCFIS was signiﬁcantly reduced at the 1- and
3-month and last follow-up (P < 0·001) (Fig. 5a); only two
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Table 2 Anorectal manometry data
Follow-up
Baseline 1 month 3 months Last P*
Functional anal canal length (cm) 3·0(1·2) 3·6(1·0) 3·5(1·1) 3·5(0·8) 0·065
Maximum resting pressure (mmHg) 79·0(30·8) 81·7(31·2) 81·0(29·2) 73·8(33·8) 0·872
Mean resting pressure (mmHg) 36·1(14·0) 37·7(15·0) 38·6(17·6) 34·5(16·5) 0·910
Squeeze pressure (mmHg) 90·5(66·4) 103·5(63·6) 93·0(58·9) 76·8(59·8) 0·102
Threshold rectal sensation (ml) 59·3(31·7) 73·4(44·1) 73·9(42·0) 75·0(38·0) 0·115
Urge rectal sensation (ml) 105·6(42·8) 121·1(55·3) 124·6(45·4) 131·1(49·9) 0·097
Rectal maximum tolerated volume (ml) 153·9(52·5) 181·4(74·5) 179·3(68·7) 190·0(60·5) 0·084
Values are mean(s.d.). *Baseline versus 1m o n t hversus 3m o n t h sversus last follow-up (Wilcoxon test). There were no signiﬁcant differences between
follow-up and baseline values.
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Fig. 3 Mean(s.d.) number of episodes of major faecal
incontinence (FI) overall, to liquid and to solid faeces at baseline
and last follow-up after Gatekeeper
TM
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Fig. 4 Number of patients affected by soiling and symptom
frequency at baseline and last follow-up after Gatekeeper
TM
implantation. P = 0·028 (Fisher’s exact test)
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Fig. 5 Mean(s.d.) a Cleveland Clinic faecal incontinence score (CCFIS) and b Vaizey score at baseline and during follow-up after
Gatekeeper
TM implantation. a P < 0·001, b P = 0·010 (Wilcoxon test)
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of 13 patients had a CCFIS higher than 7 at the ﬁnal
evaluation. Mean Vaizey score changed from a baseline of
15·4(3·3) to 7·1(3·9), 4·7(3·0) and 6·9(5·0) at 1-month, 3-
monthandlastfollow-uprespectively(P = 0·010)(Fig. 5b).
There was no correlation between anal sphincter defect
on EUS and clinical outcome, with no differences between
the subset of patients without sphincter lesions and those
with sphincter disruption.
a  7 days – coronal view b  7 days – longitudinal view
c  1 month d  3 months
Fig. 6 Endoanal ultrasound imaging at a,b 7d a y s( a coronal view, b longitudinal view), c 1 month and d 3 months after implantation of
Gatekeeper
TM prostheses (arrows)
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Mean anal manometric values did not change compared
with baseline during follow-up (Table 2). A slight increase
was noted in mean functional anal canal length and
rectal sensation, but there were no statistically signiﬁcant
changes.
One week after implantation, EUS conﬁrmed the cor-
rect position of the prostheses. EUS also demonstrated the
shape modiﬁcation of prostheses following implantation;
they appeared thicker, slightly shorter and anechoic.
During follow-up, no inﬂammatory reactions were doc-
umented by EUS around the implanted prostheses, and
there was no evidence of prosthesis displacement (Fig. 6).
After implantation of Gatekeeper
TM
,t h e r ew a sa
signiﬁcant increase in mean scores in the physical function,
rolephysical,generalhealth,socialfunction,roleemotional
and mental health domains of the SF-36 at the last
follow-up (P = 0·002, P = 0·001, P = 0·010, P < 0·001,
P < 0·001 and P = 0·001 respectively) (Fig. 7a). All FIQL
questionnaire items showed a signiﬁcant improvement in
values at ﬁnal follow-up compared with baseline: lifestyle
(P = 0·001), coping and behaviour(P < 0·001), depression
and self-perception (P < 0·001) and embarrassment (P =
0·001) (Fig. 7b).
Discussion
Atthetimethisstudywasdesigned,Gatekeeper
TM
wasused
only in patients with gastro-oesophageal reﬂux disease
(GORD). In 2008, however, the commercial licence for
GORD was discontinued and enrolment for the present
study was interrupted. The patients already enrolled were
followed up according to the study protocol. In the
meantime another company acquired the production line
and recently obtained the EC mark of approval speciﬁcally
for the use of Gatekeeper
TM
in FI, making this new bulking
agent available on the market again.
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Gatekeeper
TM
prostheses are made of a unique material
(HYEXPAN
TM
) that is solid at the time of delivery, but
slowly absorbs water and expands once implanted. Within
48 h the prosthesis has reached its ﬁnal size and shape. At
this stage the consistency of the material has changed from
hard to soft, giving the implant a pliable texture that makes
itcomplianttoexternalpressureswithoutlosingitsoriginal
shape.Forthesereasonsitwasdecidedtoplacetheimplants
in the intersphincteric space, in the belief that this would
achieve a more effective distribution of the bulking effect
than would be achieved with submucosal positioning, and
thus exploiting the physical characteristic of the implant
most effectively. The intersphincteric location should
also minimize the potential risk of erosion, ulceration,
ﬁstulationoftheanalcanalandpossibledisplacementofthe
prosthesis.Thisisparticularlyimportantinviewofthesolid
state of the prostheses at the time of implantation. In this
series there were no complications related to implantation
of the prostheses, and ultrasonographic surveillance for
a mean of almost 3 years conﬁrmed that none of the
implantshadbecomedisplaced.Theultrasoundresultsalso
showed that the size of all prostheses remained virtually
unchanged over time, thus conﬁrming the durability of
the Gatekeeper
TM
. The present cohort included not only
patients with an intact IAS but also those with an IAS
tear, or both IAS and EAS defects; patients with isolated
EAS defects, however, were excluded. The prostheses were
placed in the same position in all patients, irrespective of
the location of the sphincter lesion.
Skin incisions were made about 2 cm away from the anal
verge to minimize the risk of wound contamination during
bowel movements. The non-linear tunnelling through the
softsubcutaneoustissuestoreachtheintersphinctericplane
from the skin incision should also avoid possible prosthesis
extrusion along the track. Prosthesis placement was per-
formedunderEUS guidance,tocontroltheprocedurestep
by step and ensure correct positioning of the prostheses.
The operator could easily reach the intersphincteric space
and decide on the exact position for each prosthesis. More-
over, the introducer could be followed by direct vision
and digital palpation, and visualized by EUS. Therefore,
lesions in the rectoanal mucosal/submucosal layer could be
avoided. The contribution of EUS during Gatekeeper
TM
placement was fundamental to guiding placement of the
prosthesis. However, the authors do not believe that it is
necessarily mandatory; the procedure could be performed
safely under digital guidance by an experienced clinician.
Four prostheses were always implanted; this choice was
arbitrary but seemed effective. The prostheses were placed
at 3, 6, 9 and 12 o’clock positions for convenience but it is
likely that,provided the implants are inserted correctly and
distributed equally around the anal canal, the actual posi-
tion may not inﬂuence the outcome. Whether the number
of prostheses implanted inﬂuencesthe outcome is not clear
at this stage.
In recent literature reviews, Vaizey and Kamm12 and
Vaizey and Maeda13 analysed available data on the
various bulking agents used in FI. A paucity of reports
concerning different types of agent makes it difﬁcult to
establish which is truly effective. In a Cochrane review,
Maeda and colleagues14 found only four eligible random-
ized trials7,15–17, including a total of 176 patients treated
with injectable bulking agents: hydrogel cross-linked
with polyacrylamide (Bulkamid
TM
; Contura, Soeborg,
Denmark)7, porcine dermal collagen (Permacol
TM
;C o v i -
dien, Dublin, Ireland)7, polydimethylsiloxane elastomer
implants15,16, silicone biomaterial (PTQ
TM
; Uroplasty,
Geleen, The Netherlands)17 and carbon-coated beads
(Durasphere; Carbon Medical Technologies, St Paul,
Minnesota, USA)17. Unfortunately, the review authors
found signiﬁcant concerns of bias in all trials but one.
They were unable to demonstrate signiﬁcant effectiveness
of perianal injection of bulking agents owing to the limited
number of identiﬁed trials together with methodological
weaknesses. Moreover, with limited follow-up (maximum
12 months) only a short-term beneﬁt from injections was
reported, regardless of the material used. A silicone bio-
material (PTQ
TM
) provided some advantages and was safer
in treating FI than carbon-coated beads (Durasphere)
in the short term. However, PTQ
TM
did not show obvi-
ous clinical beneﬁt compared with normal saline injection.
Delivery of the bulking agent under ultrasound guidance,
compared with digital guidance, was more effective.
The major problem with other anal bulking agents
used so far is their reduced efﬁcacy with time, probably
due to a variable combination of degradation and/or
diffusionthroughthetissueadjacenttotheinjectionsiteor,
sometimes,farfromthatsite(Contigen,Bard,Covington,
Georgia, USA; Zuidex
TM
, Q-Med, Uppsala, Sweden). The
presentdatasuggestthattheGatekeeper
TM
overcomesallof
these potential problems. In this preliminary experience,
implantation of the Gatekeeper
TM
in the anal canal was
safe, without any morbidity, either during or after surgery.
The entire procedure was painless and well tolerated.
Wounds healed in all patientsand no discomfort was noted
either at rest or on defaecation. Adverse events, sometimes
severe, have been described for some other bulking agents
used in urinary incontinence or FI, including pulmonary
embolism, fatal stroke, periurethral mass and suspected
diseasetransmission18–21.Noadverseeventswerereported
in the present series.
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Of utmost importance was the signiﬁcant improvement
in episodes of major FI and both CCFIS and Vaizey
score. Ability to postpone defaecation for longer and
postevacuation soiling were both signiﬁcantly improved in
the majority of patients. Of note was the improvement in
both SF-36 and FIQL scores in this series, suggesting
regained health and quality of life in patients treated
with Gatekeeper
TM
. Furthermore, ﬁndings observed in the
short and medium term appeared substantially unchanged
at the ﬁnal evaluation. This is important as some of
the other bulking agents demonstrated very poor long-
term results and have had no further clinical use despite
preliminary reports suggesting good clinical effectiveness
(polytetraﬂuoroethylene, autologous fat1,2).
This preliminary study demonstrated that the
Gatekeeper
TM
anal implant was a safe, reliable and effective
treatment for FI, with results maintained over time. These
results call for larger series and longer follow-up better to
establish the role of the Gatekeeper
TM
in the management
of FI.
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Commentary
Novel bulking agent for faecal incontinence (Br J Surg 2011; 98: 1644–1652)
Faecal incontinence occurs in up to 20 per cent of the population. In addition to medical morbidity, it causes substantial
social morbidity, resulting in isolation and a considerable reduction in quality of life. For many years the surgical remedies
for this distressing problem were few, and even these were rarely successful in the long term. In the past two decades, not
only has the number of available treatments increased, but also these newer treatments are much less invasive. This makes
them more readily available to the elderly and frail, who comprise a large proportion of those affected.
One new treatment is that of injectable anal bulking agents. This paper by Ratto and colleagues introduces a new type
of bulking agent: the anal Gatekeeper
TM
(originally from Medtronic, Minneapolis, Minnesota, USA; now from THD,
Correggio, Italy). By use of extensively validated methodologies, these data suggest that the Gatekeeper
TM
is not only safe,
but also efﬁcacious. The worst features of faecal incontinence (frequency of incontinence and time to defer defaecation)
were signiﬁcantly changed for the better; quality of life was signiﬁcantly increased. These results were maintained over a
mean follow-up of nearly 3 years, in a heterogeneous group of patients. Although the study contained few patients, the
results are very encouraging. This particular bulking agent has the advantages that it can be placed accurately and that it
does not seem to deteriorate over time.
Now that there are effective, safe options for this socially disabling problem, the challenge remains to determine which
treatment best suits each patient. In this paper, Ratto and co-workers agree with the view of others1 that there is a shortage
of good-quality data in this area. Larger studies that include classiﬁcation of patients into appropriate groups2 will surely
be of immense beneﬁt to many people.
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